JP7051853B2 - ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド - Google Patents

ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド Download PDF

Info

Publication number
JP7051853B2
JP7051853B2 JP2019528746A JP2019528746A JP7051853B2 JP 7051853 B2 JP7051853 B2 JP 7051853B2 JP 2019528746 A JP2019528746 A JP 2019528746A JP 2019528746 A JP2019528746 A JP 2019528746A JP 7051853 B2 JP7051853 B2 JP 7051853B2
Authority
JP
Japan
Prior art keywords
methyl
pyrazole
phenoxy
pyrrolidine
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535799A5 (cg-RX-API-DMAC7.html
JP2019535799A (ja
Inventor
アローラ，カピルデブ・カシュミライラル
ブロドニー，マイケル・アーロン
ダン，マシュー・フランシス
グリーン，マイケル・エリック
カブラオイ，ナターシャ・マリアム
カーフマン，グレゴリー・ウェイン
メンテ，スコット・リチャード
モンゴメリー，ジャスティン・イアン
ランキック，ダニカ，アントニア
ロジャース，ブルース・ネルセン
バーホースト，パトリック・ロバート
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2019535799A publication Critical patent/JP2019535799A/ja
Publication of JP2019535799A5 publication Critical patent/JP2019535799A5/ja
Application granted granted Critical
Publication of JP7051853B2 publication Critical patent/JP7051853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019528746A 2016-11-28 2017-11-27 ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド Active JP7051853B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662426980P 2016-11-28 2016-11-28
US62/426,980 2016-11-28
US201762576435P 2017-10-24 2017-10-24
US62/576,435 2017-10-24
US201762585016P 2017-11-13 2017-11-13
US62/585,016 2017-11-13
PCT/IB2017/057418 WO2018096510A1 (en) 2016-11-28 2017-11-27 Heteroarylphenoxy benzamide kappa opioid ligands

Publications (3)

Publication Number Publication Date
JP2019535799A JP2019535799A (ja) 2019-12-12
JP2019535799A5 JP2019535799A5 (cg-RX-API-DMAC7.html) 2021-01-14
JP7051853B2 true JP7051853B2 (ja) 2022-04-11

Family

ID=60782279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528746A Active JP7051853B2 (ja) 2016-11-28 2017-11-27 ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド

Country Status (18)

Country Link
US (1) US10316021B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544972B8 (cg-RX-API-DMAC7.html)
JP (1) JP7051853B2 (cg-RX-API-DMAC7.html)
CN (1) CN110234638B (cg-RX-API-DMAC7.html)
AU (1) AU2017365123B2 (cg-RX-API-DMAC7.html)
DK (1) DK3544972T3 (cg-RX-API-DMAC7.html)
ES (1) ES2947293T3 (cg-RX-API-DMAC7.html)
FI (1) FI3544972T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230518T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061945T2 (cg-RX-API-DMAC7.html)
IL (1) IL266962B (cg-RX-API-DMAC7.html)
MX (1) MX389806B (cg-RX-API-DMAC7.html)
PH (1) PH12019501172A1 (cg-RX-API-DMAC7.html)
PL (1) PL3544972T3 (cg-RX-API-DMAC7.html)
PT (1) PT3544972T (cg-RX-API-DMAC7.html)
RS (1) RS64258B1 (cg-RX-API-DMAC7.html)
TW (1) TWI720272B (cg-RX-API-DMAC7.html)
WO (1) WO2018096510A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018223177B2 (en) * 2017-02-24 2024-05-02 Xeniopro GmbH Aromatic compounds which enhance notch signaling, for use in therapy
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
CR20210563A (es) * 2020-04-05 2022-01-24 Pfizer Compuestos y métodos para el tratamiento de covid-19
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
IL315411A (en) * 2022-03-07 2024-11-01 Janssen Pharmaceuticals Inc Pure forms of crystalline eticarpant
US11998524B2 (en) * 2022-03-07 2024-06-04 Janssen Pharmaceuticals, Inc. Forms of aticaprant
CN120019046A (zh) * 2022-10-12 2025-05-16 安道麦马克西姆有限公司 用于制备氨基哒嗪衍生物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
JP2011524850A (ja) 2008-01-22 2011-09-08 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
CN1305852C (zh) 2002-09-19 2007-03-21 伊莱利利公司 作为阿片受体拮抗剂的二芳基醚
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
JP2006519855A (ja) 2003-03-07 2006-08-31 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニスト
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
EP1849835B1 (en) 2005-02-18 2017-08-30 Nippon Soda Co., Ltd. Organic-inorganic composite body
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EA014820B1 (ru) 2006-04-04 2011-02-28 Эмодис Гмбх Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
CR11559A (es) 2008-03-25 2010-10-20 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
CA3031835C (en) 2008-06-27 2021-09-07 Celgene Car Llc Heteroaryl compounds and uses thereof
US8609696B2 (en) 2008-12-18 2013-12-17 Boehringer Ingelheim International Gmbh Serotonin 5-HT2B receptor inhibitors
HN2010001319A (es) 2009-01-26 2013-01-15 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
US20150274657A1 (en) 2012-10-02 2015-10-01 Merck Patent Gmbh Pyrrolidines
WO2015109080A1 (en) 2014-01-15 2015-07-23 Research Triangle Institute Kappa-opioid receptor selective opioid receptor antagonists
US10118896B2 (en) 2014-11-26 2018-11-06 University Of Kansas Antagonists of the kappa opioid receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
JP2011524850A (ja) 2008-01-22 2011-09-08 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Also Published As

Publication number Publication date
NZ754862A (en) 2024-11-29
EP3544972A1 (en) 2019-10-02
PT3544972T (pt) 2023-06-20
TW201831460A (zh) 2018-09-01
IL266962B (en) 2022-02-01
ES2947293T3 (es) 2023-08-04
JP2019535799A (ja) 2019-12-12
EP3544972B8 (en) 2023-06-07
TWI720272B (zh) 2021-03-01
US10316021B2 (en) 2019-06-11
US20180148432A1 (en) 2018-05-31
CN110234638A (zh) 2019-09-13
HRP20230518T1 (hr) 2023-08-04
EP3544972B1 (en) 2023-04-26
FI3544972T3 (fi) 2023-06-02
CA3045242A1 (en) 2018-05-31
PH12019501172A1 (en) 2019-12-11
DK3544972T3 (da) 2023-05-30
MX389806B (es) 2025-03-20
IL266962A (en) 2019-07-31
WO2018096510A1 (en) 2018-05-31
RS64258B1 (sr) 2023-07-31
AU2017365123A1 (en) 2019-07-11
HUE061945T2 (hu) 2023-09-28
PL3544972T3 (pl) 2023-07-24
CN110234638B (zh) 2022-10-21
MX2019006220A (es) 2019-10-07
AU2017365123B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP7051853B2 (ja) ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド
JP6294918B2 (ja) 選択的ＮＫ−３受容体拮抗薬としての新規なキラルＮ−アシル−５，６，７，（８位置換）−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法およびキラル合成
CN114340740A (zh) β肾上腺素能激动剂及其使用方法
CN107257801B (zh) 选择性bace1抑制剂
TW201028386A (en) Novel bicyclic heterocyclic compound
JP2020506903A (ja) Ｍａｇｌ阻害薬としての複素環式スピロ化合物
JP2018527329A (ja) Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
TWI701246B (zh) 作為ＬＲＲＫ２抑制劑之新穎咪唑並［４，５－ｃ］喹啉衍生物
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
JP6929857B2 (ja) ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
JP7561777B2 (ja) 新規ｅｇｆｒ阻害剤
US10899702B2 (en) HTRPVI chemical agents
KR20210039417A (ko) 치환된 테트라하이드로사이클로펜타[c]피롤, 치환된 디하이드로피롤리진, 이의 유사체, 및 이의 사용 방법
KR20110123287A (ko) 세로토닌 및 노르에피네프린 재흡수 억제제
TWI675826B (zh) 環狀經取代之咪唑并［４，５－ｃ］喹啉衍生物
CA3045242C (en) Heteroarylphenoxy benzamide kappa opioid ligands
TW202339706A (zh) 含醯胺的ｌｏｎｐ１抑制劑化合物、用途及方法
TW202202491A (zh) 具有血清素受體結合活性之芳香族雜環衍生物
HK40014240B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
HK40014240A (en) Heteroarylphenoxy benzamide kappa opioid ligands
JP7713954B2 (ja) 核内受容体に対して活性な化合物
JP2009517483A (ja) 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体
WO2025042956A1 (en) Pde 7 modulator compounds
KR20070022753A (ko) 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
HK40000923B (zh) 一种多巴胺d3配体化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220330

R150 Certificate of patent or registration of utility model

Ref document number: 7051853

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250